Gyre Therapeutics Inc. (GYRE) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Gyre Therapeutics Inc. $0.97, price $7.40, upside -86.9%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value $0.9700 · Strongly overvalued (−87%)
!Quality 37/100
!Mixed Growth(revenue 5y +41.0 %/yr)
!Loss over the last twelve months · -5.4% net margin (TTM) · fiscal year 2025 4.3%
!negative free cash flow
!Trails peers(3/9)
!Narrow moat19/100
!Evidence only low, so the estimate is less certain
Watch Gyre Therapeutics Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $2.85 – $48.10 · fair‑value band $0.8500 – $1.42 · the $7.40 price screens above the $0.9700 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Gyre Therapeutics in your weekly email
Every Wednesday you see whether Gyre Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
Show more
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Stock analysis
Gyre Therapeutics Inc. (GYRE) currently trades at $7.40, while our model-based Fair Value estimate is $0.9700, implying the stock looks roughly 662.8% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $2.41 per share, and 0 of the 15 models we run sit above the $7.40 price.
Bear case: the Asset-Based group reads lowest at $0.7300, and 15 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.8500 (bear) to $1.42 (bull), the price of $7.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Gyre Therapeutics Inc. reported revenue of $117M in FY2025 versus $7.3M in FY2021, a compound +99.6%/yr. Reported net income was $5.0M in FY2025.
Key figures
Market cap $764M · P/S ratio 5.18 · EPS (TTM) $−0.0800 · Net margin 4.3% · Return on equity −3.1% · Return on assets (EBIT) −35.5% · Operating margin −30.2% · Revenue (TTM) $117M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −87%, GYRE screens richer than that median.
Fair Value models
Bear $0.8500Fair Value $0.9700Bull $1.42
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.0%
Start year 2020 (pandemic). Over 10 years: +52.2% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
’09
’10
’11
’12
’13
’15
’17
’20
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−14.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−274% → 10%
⚠ Revenue per share shrinking 18.9%/yr over ~11Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 653 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Below median
Fair Value upside−87% · Bottom 25%
Profitability
Return on assets1% · Above median
Net margin (TTM)−5% · Below median
Operating margin (TTM)−30% · Bottom 25%
Growth and dividend
Revenue growth2% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B7.20× · Priciest 25%
P/S (TTM)6.52× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)11· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Gyre Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/GYRE
Frequently asked questions
Is Gyre Therapeutics Inc. (GYRE) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.9700 versus a price of $7.40, about −87% upside (overvalued).
What is the fair value of GYRE?
Our model-based fair value for Gyre Therapeutics Inc. is $0.9700 (as of Sep 23, 2026), built from audited fundamentals. The current price: $7.40.
What is the quality score of GYRE?
Gyre Therapeutics Inc. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gyre Therapeutics Inc. (GYRE)?
Our model-based price target is the fair value of $0.9700 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario $0.8500, optimistic scenario $1.42. It is a calculation from audited fundamentals, not an analyst target.
What is the Gyre Therapeutics Inc. stock forecast for 2026?
Our models put fair value at $0.9700, about −87% upside versus a price of $7.40 (overvalued). Cautious scenario $0.8500, optimistic scenario $1.42. The calculation is refreshed regularly with new filings.
What is the revenue of Gyre Therapeutics Inc. (GYRE)?
Gyre Therapeutics Inc. reported trailing-twelve-month revenue of about $117M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Gyre Therapeutics Inc. (GYRE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gyre Therapeutics Inc. it is $0.9700 per share (as of Sep 23, 2026), against a price of $7.40. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Gyre Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, GYRE trades above its calculated fair value: price $7.40, fair value $0.9700, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GYRE?
No. The price is what the market pays today ($7.40); the fair value is what the company's own numbers justify ($0.9700). For Gyre Therapeutics Inc. the two are $6.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gyre Therapeutics Inc. worth?
The market values Gyre Therapeutics Inc. at about $764M (market capitalisation, as of Sep 23, 2026). Per share that is $7.40; our models calculate a fair value of $0.9700 per share.
What do the bullish and bearish scenarios say about GYRE?
Our models span a range for Gyre Therapeutics Inc.: cautious scenario $0.8500, base $0.9700, optimistic $1.42 per share (as of Sep 23, 2026, price $7.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gyre Therapeutics Inc. (GYRE)?
Balance-sheet figures for Gyre Therapeutics Inc. (as of Sep 23, 2026): return on equity −3.1%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is GYRE from its 52-week high?
Gyre Therapeutics Inc. trades at $7.40, about 17% below its 52-week high of $8.87 and 33% above the low of $5.56 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9700 is for.
Which stocks are comparable to Gyre Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gyre Therapeutics Inc. stock attractive at the current price?
The data as of Sep 23, 2026: price $7.40, calculated fair value $0.9700 (−87%), Quality Score 37/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GYRE calculated?
We run Gyre Therapeutics Inc. through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.9700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Gyre Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gyre Therapeutics Inc. (GYRE)?
The closing price on Sep 23, 2026 was $7.40. Our model-based fair value is $0.9700, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gyre Therapeutics Inc. right now?
The price sits above even our optimistic bull case ($1.42). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Gyre Therapeutics Inc.
How large is the market capitalisation of Gyre Therapeutics Inc. (GYRE)?
The market capitalisation of Gyre Therapeutics Inc. is $764M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gyre Therapeutics Inc. (GYRE)?
The price-to-sales ratio of Gyre Therapeutics Inc. is 5.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gyre Therapeutics Inc. (GYRE)?
Earnings per share at Gyre Therapeutics Inc. are $−0.0800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Gyre Therapeutics Inc. (GYRE)?
The net margin of Gyre Therapeutics Inc. is 4.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gyre Therapeutics Inc. (GYRE)?
The return on equity (ROE) of Gyre Therapeutics Inc. is −3.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gyre Therapeutics Inc. (GYRE)?
On an EBIT basis the return on assets of Gyre Therapeutics Inc. is −35.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gyre Therapeutics Inc. (GYRE)?
The operating margin of Gyre Therapeutics Inc. is −30.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gyre Therapeutics Inc. (GYRE)?
Revenue at Gyre Therapeutics Inc. is growing +2.1% versus a year earlier (3y avg +4.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gyre Therapeutics Inc. (GYRE)?
Earnings per share at Gyre Therapeutics Inc. are growing +166% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Gyre Therapeutics Inc. (GYRE) generate?
The free cash flow of Gyre Therapeutics Inc. is −$180K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Gyre Therapeutics Inc. (GYRE) hold?
Gyre Therapeutics Inc. holds more cash than debt, $36.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Gyre Therapeutics Inc. in the live analysis
One click puts Gyre Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026